OS Therapies Inc
No SEC Form 4 filings for $OSTX in the last 30 days.
See all $OSTX insider activity →OS Therapies (OSTX) received USDA feedback on its OST-HER2 treatment for canine osteosarcoma. The company is reviewing strategic alternatives for its subsidiary, OS Animal Health (OSAH), which plans a crowdfunding campaign. The veterinary oncology market is projected to grow to $4.77B by 2034, according to Towards Healthcare.
OS Therapies reported 72.7% 3-year survival in Phase 2b trial for OST-HER2 vs 45.8% in controls. The company plans regulatory filings and a Phase 3 study. The trial involved 41 patients, with 4 lost to follow-up.
OS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 October 1, 2026 OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company’s lead product candidate H
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning OSTX (OS Therapies Inc). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent OSTX coverage spans regulation, corporate actions and financial news.
Regulatory feedback creates uncertainty; approval could boost valuation, while delays may pressure the stock.
Positive Phase 2b data may lift the stock on expectations of accelerated approval and future revenue.
Executive hires signal preparation for commercial launch, potentially supporting near‑term share demand.
Executive appointments signal progress toward commercialization, which may modestly improve sentiment.
Potential near‑term upside as regulatory filings commence; long‑term value tied to BLA and PRV prospects.
AlphAI scores every news story that mentions OSTX with an AI model for sentiment and relevance, and aggregates insider trades from OS Therapies Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
OS Therapies (OSTX) received USDA feedback on its OST-HER2 treatment for canine osteosarcoma. The company is reviewing strategic alternatives for its subsidiary, OS Animal Health (OSAH), which plans a crowdfunding campaign. The veterinary oncology market is projected to grow to $4.77B by 2034, according to Towards Healthcare.
2 min readOS Therapies reported 72.7% 3-year survival in Phase 2b trial for OST-HER2 vs 45.8% in controls. The company plans regulatory filings and a Phase 3 study. The trial involved 41 patients, with 4 lost to follow-up.
1 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 October 1, 2026 OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company’s lead product candidate H
2 min readOS Therapies (NYSE American: OSTX) appointed Kerry Clem as CCO and Frank Knuettel II as CFO. Clem will lead commercialization of Herlystic, their lead immunotherapy for osteosarcoma, with U.S. launch planned post-FDA approval. Knuettel brings financial expertise. The company anticipates regulatory filings in Q4 2026 and has received tax credits for R&D.
2 min readOS Therapies (NYSE American: OSTX) announced that the World Health Organization approved 'Herlystic' as the brand name for OST-HER2, a gene-edited cancer immunotherapy. The company plans to initiate regulatory submissions for early market access in the U.K., U.S., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, and the company aims to file for a Biologics License Application in the U.S. in 2026.
2 min readOS Therapies (OSTX) updated its global regulatory coordination for OST-HER2 under Project Orbis. The U.K.'s MHRA will lead the process, with a Phase 3 trial set to begin in mid-2026. The FDA aligned on the study design, and the company aims to submit a CMAA soon. OST-HER2 has received multiple designations from the FDA, EMA, and MHRA.
2 min readOS Therapies (OSTX) aligned with the FDA on its Phase 3 trial design for OST-HER2, a treatment for metastatic osteosarcoma. The company will join Project Orbis, a global regulatory initiative, and aims to submit a BLA in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, and a successful BLA could make the company eligible for a Priority Review Voucher.
2 min readOS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.
2 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 10, 2026, OS Therapies Incorporated (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), which forms a part of the Company’s registration statement on Form S
1 min readOS Therapies Inc (OSTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2026, the stockholders of OS Therapies Incorporated (the “Company”) approved and adopted the amendment and
1 min read
